Summary
A bioRxiv preprint reports that ibuprofen increased ciprofloxacin tolerance in Campylobacter jejuni in a screen of 2,415 small molecules. The same study identified human-targeted drugs that inhibited the bacterium while sparing commensal microbes.
A bioRxiv preprint posted on 6 October 2026 reports that ibuprofen increased the foodborne bacterium Campylobacter jejuni’s tolerance to ciprofloxacin in a screen of 2,415 host-relevant small molecules. The study also found human-targeted drugs that inhibited the pathogen while sparing commensal microbes. These are findings from a chemical-genomics screen, not a clinical study.
What the screen found
The researchers used a transcriptional chemical-genomics approach to track how compounds affected stress-responsive promoters and bacterial fitness. Promoters are DNA regions that help control when genes are switched on; monitoring their activity can reveal how a bacterium responds to chemical stress.
The screen found that diverse compounds activated expression of CmeABC, an efflux pump in C. jejuni. Efflux pumps move substances out of bacterial cells. The authors report that ibuprofen, a widely used non-steroidal anti-inflammatory drug, induced CmeABC expression and thereby increased the bacterium’s tolerance to ciprofloxacin, an antibiotic.
The study also identified multiple human-targeted drugs with growth-inhibitory activity against C. jejuni that spared commensal bacteria. This points to a second possibility: some compounds might suppress the pathogen without affecting those beneficial microbes in the same way. The abstract does not name these additional drugs or quantify the reported effects.
Why the findings matter
The results suggest that medicines developed for human targets can have different, and potentially opposing, effects on bacteria: some may alter antibiotic responses, while others may inhibit a pathogen selectively. That makes the effects of non-antibiotic drugs on bacterial physiology relevant to research on antimicrobial resistance and drug repurposing.
The findings are from a bioRxiv preprint. They identify responses in a bacterial screening study; they do not report whether ibuprofen changes ciprofloxacin treatment outcomes in people. The reported drug effects therefore need to be understood as research leads rather than clinical guidance.